The webinar is broken out into two parts:
Part 1: Biologics – The first part of the presentation focused on biologics, including an explanation of the high level of precision that is required to produce a consistent biological product each time.
Part 2: Biosimilars – The second part of the presentation focused on the growing interest in biosimilars, followed by what we can learn from Europe’s experience. Also provided were Health Canada’s position on biosimilars, discussion on key issues surrounding biosimilars relevant to the Canadian market, as well as, the importance of patient safety and patient choice.
Following the presentation, there was an interactive discussion where listeners had an opportunity to ask questions and continue the dialogue on biologic medicines and biosimilars.